IGM Biosciences, Inc.
IGMS · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.01 | 0.06 | -0.15 |
| FCF Yield | -73.78% | -46.28% | -9.65% | -3.95% |
| EV / EBITDA | 0.39 | -2.53 | -10.61 | -16.21 |
| Quality | ||||
| ROIC | 129.09% | -29.50% | -16.57% | -24.09% |
| Gross Margin | 99.69% | 100.00% | -471.12% | 100.00% |
| Cash Conversion Ratio | -0.52 | 0.61 | 0.95 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | 342.60% | 19.00% | 35.83% | 61.17% |
| Free Cash Flow Growth | -56.04% | 8.78% | 10.07% | -2.82% |
| Safety | ||||
| Net Debt / EBITDA | -0.31 | -0.23 | -0.51 | -0.05 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -489.07 | 0.00 | 137.16 | 0.00 |